Advertisement
Advertisement
SPRY
ARS Pharmaceuticals, Inc. Common Stock
7.95
USDSponsored
-2.59
-24.57%
Jun 25, 11:09 UTC -4
Open
SPRY Earnings Reports
Positive Surprise Ratio
SPRY beat 11 of 22 last estimates.
50%
Next Report
Date of Next Report
Aug 11, 2026
Estimate for Q2 26 (Revenue/ EPS)
$32.82M
/-$0.53
Implied change from Q1 26 (Revenue/ EPS)
+44.71%
/-13.11%
Implied change from Q2 25 (Revenue/ EPS)
+108.83%
/+15.22%
ARS Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On May 15, 2026, SPRY reported earnings of -0.61 USD per share (EPS) for Q1 26, missing the estimate of -0.53 USD, resulting in a -13.81% surprise. Revenue reached 22.68 million, compared to an expected 22.67 million, with a 0.03% difference. The market reacted with a -6.49% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of -0.53 USD, with revenue projected to reach 32.82 million USD, implying an decrease of -13.11% EPS, and increase of 44.71% in Revenue from the last quarter.
FAQ
What were ARS Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, ARS Pharmaceuticals, Inc. Common Stock reported EPS of -$0.61, missing estimates by -13.81%, and revenue of $22.68M, 0.03% above expectations.
How did the market react to ARS Pharmaceuticals, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -6.49%, changed from $7.94 before the earnings release to $7.42 the day after.
When is ARS Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 11, 2026.
What are the forecasts for ARS Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 6
analysts, ARS Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.53 and revenue of $32.82M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement